FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W913623683> ?p ?o ?g. }

• W913623683 endingPage "945" @default.
• W913623683 startingPage "939" @default.
• W913623683 abstract "Androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) was recently demonstrated to be associated with resistance to abiraterone and enzalutamide. Cabazitaxel might, however, remain effective in AR-V7-positive patients. To investigate the association between AR-V7 expression in CTCs and resistance to cabazitaxel. We selected patients with mCRPC from the multicenter, randomized, phase 2, randomized, open-label, multicenter study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel (Jevtana) (CABARESC). Before the start of the first and third cabazitaxel cycle, CTCs were enumerated using the CellSearch System. In patients with ≥10 CTCs in 7.5 ml blood at baseline, the expression of AR-V7 was assessed by quantitative polymerase chain reaction. The primary end point was the association between the AR-V7 status and the CTC response rate (decrease to fewer than five CTCs in 7.5 ml blood during treatment). Secondary end points were the prostate-specific antigen (PSA) response rate (RR) and overall survival (OS). Analyses were performed using chi-square and log-rank tests. AR-V7 was detected in 16 of 29 patients (55%) with ≥10 CTCs and was more frequently found in abiraterone pretreated patients (5 of 5 [100%] treated vs 7 of 20 [35%] untreated; p = 0.009). We found no differences in CTC and PSA RRs. The presence of AR-V7 in CTCs was not associated with progression-free survival (hazard ratio [HR]: 0.8; 95% confidence interval [CI], 0.4–1.8) or overall survival (HR 1.6; 95% CI, 0.6–4.4). The response to cabazitaxel seems to be independent of the AR-V7 status of CTCs from mCRPC patients. Consequently, cabazitaxel might be a valid treatment option for patients with AR-V7-positive CTCs. Tools are needed to select specific treatments for specific patients at specific times. The presence of the gene AR-V7 in CTCs has been associated with resistance to anti-androgen receptor treatments. We investigated whether this holds true for cabazitaxel, but we found cabazitaxel to be effective independent of the presence of AR-V7." @default.
• W913623683 created "2016-06-24" @default.
• W913623683 creator A5007844500 @default.
• W913623683 creator A5010797456 @default.
• W913623683 creator A5014770720 @default.
• W913623683 creator A5022173747 @default.
• W913623683 creator A5031865542 @default.
• W913623683 creator A5034635531 @default.
• W913623683 creator A5041093711 @default.
• W913623683 creator A5041610986 @default.
• W913623683 creator A5045768916 @default.
• W913623683 creator A5047006962 @default.
• W913623683 creator A5047764279 @default.
• W913623683 creator A5047837719 @default.
• W913623683 creator A5047950538 @default.
• W913623683 creator A5066680524 @default.
• W913623683 creator A5066926133 @default.
• W913623683 creator A5074174053 @default.
• W913623683 creator A5078332643 @default.
• W913623683 creator A5086664857 @default.
• W913623683 date "2015-12-01" @default.
• W913623683 modified "2023-10-18" @default.
• W913623683 title "Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells" @default.
• W913623683 cites W1512914561 @default.
• W913623683 cites W1594723233 @default.
• W913623683 cites W1844925317 @default.
• W913623683 cites W1967774964 @default.
• W913623683 cites W1969202480 @default.
• W913623683 cites W1996389184 @default.
• W913623683 cites W2014077960 @default.
• W913623683 cites W2082239705 @default.
• W913623683 cites W2100115202 @default.
• W913623683 cites W2101500128 @default.
• W913623683 cites W2103793201 @default.
• W913623683 cites W2108679313 @default.
• W913623683 cites W2112564453 @default.
• W913623683 cites W2116607127 @default.
• W913623683 cites W2122739907 @default.
• W913623683 cites W2123526148 @default.
• W913623683 cites W2127307826 @default.
• W913623683 cites W2129128353 @default.
• W913623683 cites W2137467802 @default.
• W913623683 cites W2144724357 @default.
• W913623683 cites W2148643283 @default.
• W913623683 cites W2148998801 @default.
• W913623683 cites W2156923287 @default.
• W913623683 cites W2166918329 @default.
• W913623683 cites W2167331614 @default.
• W913623683 cites W2168108459 @default.
• W913623683 doi "https://doi.org/10.1016/j.eururo.2015.07.007" @default.
• W913623683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26188394" @default.
• W913623683 hasPublicationYear "2015" @default.
• W913623683 type Work @default.
• W913623683 sameAs 913623683 @default.
• W913623683 citedByCount "211" @default.
• W913623683 countsByYear W9136236832015 @default.
• W913623683 countsByYear W9136236832016 @default.
• W913623683 countsByYear W9136236832017 @default.
• W913623683 countsByYear W9136236832018 @default.
• W913623683 countsByYear W9136236832019 @default.
• W913623683 countsByYear W9136236832020 @default.
• W913623683 countsByYear W9136236832021 @default.
• W913623683 countsByYear W9136236832022 @default.
• W913623683 countsByYear W9136236832023 @default.
• W913623683 crossrefType "journal-article" @default.
• W913623683 hasAuthorship W913623683A5007844500 @default.
• W913623683 hasAuthorship W913623683A5010797456 @default.
• W913623683 hasAuthorship W913623683A5014770720 @default.
• W913623683 hasAuthorship W913623683A5022173747 @default.
• W913623683 hasAuthorship W913623683A5031865542 @default.
• W913623683 hasAuthorship W913623683A5034635531 @default.
• W913623683 hasAuthorship W913623683A5041093711 @default.
• W913623683 hasAuthorship W913623683A5041610986 @default.
• W913623683 hasAuthorship W913623683A5045768916 @default.
• W913623683 hasAuthorship W913623683A5047006962 @default.
• W913623683 hasAuthorship W913623683A5047764279 @default.
• W913623683 hasAuthorship W913623683A5047837719 @default.
• W913623683 hasAuthorship W913623683A5047950538 @default.
• W913623683 hasAuthorship W913623683A5066680524 @default.
• W913623683 hasAuthorship W913623683A5066926133 @default.
• W913623683 hasAuthorship W913623683A5074174053 @default.
• W913623683 hasAuthorship W913623683A5078332643 @default.
• W913623683 hasAuthorship W913623683A5086664857 @default.
• W913623683 hasConcept C121608353 @default.
• W913623683 hasConcept C126322002 @default.
• W913623683 hasConcept C126894567 @default.
• W913623683 hasConcept C143998085 @default.
• W913623683 hasConcept C168563851 @default.
• W913623683 hasConcept C203092338 @default.
• W913623683 hasConcept C207103383 @default.
• W913623683 hasConcept C2775832370 @default.
• W913623683 hasConcept C2776551883 @default.
• W913623683 hasConcept C2777899217 @default.
• W913623683 hasConcept C2778971682 @default.
• W913623683 hasConcept C2779013556 @default.
• W913623683 hasConcept C2780192828 @default.
• W913623683 hasConcept C2781190966 @default.
• W913623683 hasConcept C44249647 @default.

• next